• Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
  • Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
  • Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
  • Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at $0.29 per share

Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).

In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year

Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.

Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at $0.29 per share. 


More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.